AKERO THERAPEUTICS INC's ticker is AKRO and the CUSIP is 00973Y108. A total of 80 filers reported holding AKERO THERAPEUTICS INC in Q2 2020. The put-call ratio across all filers is - and the average weighting 1.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $10 | +11.1% | 188 | 0.0% | 0.00% | – |
| Q2 2023 | $9 | +28.6% | 188 | 0.0% | 0.00% | – |
| Q1 2023 | $7 | -30.0% | 188 | 0.0% | 0.00% | – |
| Q4 2022 | $10 | -99.8% | 188 | +58.0% | 0.00% | – |
| Q3 2022 | $4,000 | +300.0% | 119 | 0.0% | 0.00% | – |
| Q2 2022 | $1,000 | -50.0% | 119 | 0.0% | 0.00% | – |
| Q1 2022 | $2,000 | -33.3% | 119 | 0.0% | 0.00% | – |
| Q4 2021 | $3,000 | 0.0% | 119 | 0.0% | 0.00% | – |
| Q3 2021 | $3,000 | +50.0% | 119 | +83.1% | 0.00% | – |
| Q2 2021 | $2,000 | 0.0% | 65 | 0.0% | 0.00% | – |
| Q1 2021 | $2,000 | 0.0% | 65 | 0.0% | 0.00% | – |
| Q4 2020 | $2,000 | -60.0% | 65 | -59.6% | 0.00% | – |
| Q3 2020 | $5,000 | +66.7% | 161 | 0.0% | 0.00% | – |
| Q2 2020 | $3,000 | 0.0% | 161 | 0.0% | 0.00% | – |
| Q1 2020 | $3,000 | -25.0% | 161 | 0.0% | 0.00% | – |
| Q4 2019 | $4,000 | – | 161 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Skorpios Trust | 3,271,829 | $179,296 | 57.03% |
| Redmile Group, LLC | 2,632,912 | $144,283,578 | 5.90% |
| Avidity Partners Management LP | 3,825,000 | $209,610,000 | 4.54% |
| COMMODORE CAPITAL LP | 537,076 | $29,432 | 4.44% |
| Atlas Venture Life Science Advisors, LLC | 594,251 | $32,564,955 | 3.92% |
| Paradigm Biocapital Advisors LP | 604,544 | $33,129,011 | 3.89% |
| Yiheng Capital Management, L.P. | 1,468,905 | $80,495,994 | 3.56% |
| Altium Capital Management LP | 125,000 | $6,850,000 | 3.48% |
| Tri Locum Partners LP | 128,851 | $7,061,000 | 2.86% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 172,100 | $9,431,080 | 2.70% |